Marjorie Faure Philippe Rochigneux Daniel Olive Sébastien Taix Isabelle Brenot-Rossi Marine Gilabert
10.3389/fimmu.2018.00797
Front Immunol
2018 Apr 19;9:797.
anti-pd1 hyperprogression immune checkpoint inhibitors immunomonitoring melanoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/29725330/
Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Melanoma / drug therapy Melanoma / pathology Rectal Neoplasms / drug therapy Rectal Neoplasms / pathology
Antibodies, Monoclonal, Humanized / adverse effects Antineoplastic Agents, Immunological / adverse effects Melanoma / drug therapy Melanoma / pathology Rectal Neoplasms / drug therapy Rectal Neoplasms / pathology Case Reports Research Support, Non-U.S. Gov't Aged Disease Progression Fatal Outcome Humans Male Melanoma / immunology Neoplasm Recurrence, Local / drug therapy Neoplasm Recurrence, Local / immunology Neoplasm Recurrence, Local / pathology Rectal Neoplasms / immunology Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological pembrolizumab
PMC5916968
29725330
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
2018